AAPL   321.57 (-0.09%)
MSFT   183.36 (+0.29%)
FB   231.36 (-0.24%)
GOOGL   1,431.84 (-0.21%)
NVDA   348.51 (-1.06%)
BABA   208.86 (+1.11%)
MU   46.34 (+0.00%)
GE   7.00 (+3.55%)
AMD   53.41 (-0.41%)
T   30.88 (-0.16%)
ACB   14.30 (+1.42%)
GILD   74.07 (-1.45%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
BA   151.39 (+0.00%)
AAPL   321.57 (-0.09%)
MSFT   183.36 (+0.29%)
FB   231.36 (-0.24%)
GOOGL   1,431.84 (-0.21%)
NVDA   348.51 (-1.06%)
BABA   208.86 (+1.11%)
MU   46.34 (+0.00%)
GE   7.00 (+3.55%)
AMD   53.41 (-0.41%)
T   30.88 (-0.16%)
ACB   14.30 (+1.42%)
GILD   74.07 (-1.45%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
BA   151.39 (+0.00%)
AAPL   321.57 (-0.09%)
MSFT   183.36 (+0.29%)
FB   231.36 (-0.24%)
GOOGL   1,431.84 (-0.21%)
NVDA   348.51 (-1.06%)
BABA   208.86 (+1.11%)
MU   46.34 (+0.00%)
GE   7.00 (+3.55%)
AMD   53.41 (-0.41%)
T   30.88 (-0.16%)
ACB   14.30 (+1.42%)
GILD   74.07 (-1.45%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
BA   151.39 (+0.00%)
AAPL   321.57 (-0.09%)
MSFT   183.36 (+0.29%)
FB   231.36 (-0.24%)
GOOGL   1,431.84 (-0.21%)
NVDA   348.51 (-1.06%)
BABA   208.86 (+1.11%)
MU   46.34 (+0.00%)
GE   7.00 (+3.55%)
AMD   53.41 (-0.41%)
T   30.88 (-0.16%)
ACB   14.30 (+1.42%)
GILD   74.07 (-1.45%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
BA   151.39 (+0.00%)
Log in

NASDAQ:BOLDAudentes Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$59.97
0.00 (0.00 %)
(As of 01/15/2020)
Add
Compare
Today's Range
$59.97
Now: $59.97
$59.97
50-Day Range
$59.97
MA: $59.97
$59.97
52-Week Range
$22.00
Now: $59.97
$60.00
VolumeN/A
Average Volume1.50 million shs
Market Capitalization$2.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.18
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Read More
Audentes Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.93 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BOLD
CUSIPN/A
Phone415-818-1001

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($7.48) per share

Profitability

Net Income$-128,820,000.00

Miscellaneous

Employees207
Market Cap$2.77 billion
Next Earnings DateN/A
OptionableOptionable

Receive BOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter.

Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Audentes Therapeutics?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 13 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Audentes Therapeutics.

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics Inc (NASDAQ:BOLD) posted its earnings results on Thursday, November, 7th. The biotechnology company reported ($1.00) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.07) by $0.07. During the same quarter last year, the company earned ($0.97) EPS. View Audentes Therapeutics' earnings history.

What price target have analysts set for BOLD?

15 analysts have issued 12-month target prices for Audentes Therapeutics' stock. Their forecasts range from $10.00 to $60.00. On average, they anticipate Audentes Therapeutics' stock price to reach $50.75 in the next year. This suggests that the stock has a possible downside of 15.4%. View analysts' price targets for Audentes Therapeutics.

Has Audentes Therapeutics been receiving favorable news coverage?

News articles about BOLD stock have been trending very positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Audentes Therapeutics earned a media sentiment score of 3.5 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAudentes Therapeutics.

Who are some of Audentes Therapeutics' key competitors?

What other stocks do shareholders of Audentes Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Crispr Therapeutics (CRSP), Energy Transfer LP Unit (ET), Gilead Sciences (GILD), Clovis Oncology (CLVS), Intel (INTC), AbbVie (ABBV), Exelixis (EXEL), Ford Motor (F), Global Blood Therapeutics (GBT) and Myriad Genetics (MYGN).

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the following people:
  • Mr. Matthew R. Patterson, Co-Founder, Chairman & CEO (Age 47)
  • Ms. Natalie C. Holles, Pres & COO (Age 46)
  • Mr. Thomas P. Soloway, Exec. VP & CFO (Age 52)
  • Dr. John T. Gray, Sr. VP & Chief Scientific Officer (Age 56)
  • Mr. Andrew H. Chang, Director of Investor Relations

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an initial public offering on Wednesday, July 20th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

What is Audentes Therapeutics' stock price today?

One share of BOLD stock can currently be purchased for approximately $59.97.

How big of a company is Audentes Therapeutics?

Audentes Therapeutics has a market capitalization of $2.77 billion. The biotechnology company earns $-128,820,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 207 workers across the globe.

What is Audentes Therapeutics' official website?

The official website for Audentes Therapeutics is www.audentestx.com.

How can I contact Audentes Therapeutics?

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.